<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of patients with von Hippel-Lindau disease and locoregional renal cell carcinoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of patients with von Hippel-Lindau disease and locoregional renal cell carcinoma</h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment of patients with von Hippel-Lindau disease and locoregional renal cell carcinoma</div><div class="cntnt"><img src="data:png;base64,iVBORw0KGgoAAAANSUhEUgAAAbMAAAGdBAMAAABqZYDyAAAACXBIWXMAAAPoAAAD6AG1e1JrAAAAJ1BMVEX///8AAACIiIjBwcEbGxtERETj4+NmZmaZmZkzMzNVVVV3d3eqqqrK4jibAAAWq0lEQVR42uzdz3Pa2B0A8C8SEhj7oK8lC0h9ELXoxNOL1JDtZNqDZLKEbXIAdtMk4x6ETci4J9H88LR7gYTdnfRkti2bzvRgzzSTzvaSzOSUk3c307+r74nECdjx4h8YxH6/ByIIY/HR972n9+DpCYCCgoKCgoKCIiwRwVOMCaNN6N8iGtGIFnKaUBp8mxVKmoTzwYd/+/HVQVpWMsJK823r/bzso0GIadE25htYtXbSa5fTd1AH4XK6jun1zjmADfSzLWx1UnInKWWdTMhoLQ+usgL5q+7Mzwu1Js8a+weq32+xNzyT87xAGmbCr13sQshomLqDSUb7NeKfStGAVoo+KuOXO08AXEwFda0dRfzCCF2BhJb3TWSXZY2bmosB7autahNMljXejDxntITP6lzYsuazCnUlxusaPmS0hh5kzXUfYorXNT0bx5bVljt4O2w06o0QjWhEI9owH0dU+p5m+zqS4aWVsRu5oPSBPkD7QGd5ImkzfFxzQ17pZW0aaXmWtRY+wCTv7mda7AHA7uQFzEc6KamTFCr6Ttrb0Rq4hn+LuEncug+rYaCV8QkvkHE9y7v7phVsgW3dyFmvWM9fKtlreYEPDljWbOt+xLhXV6t1PRRZg0z1gvKY9RmD7j4EW2DDZgs1hrltVNdKMcRNn9HakItYWVClX/phaEZugMloV+f05aC7D2yrR8tZDPNS4jSBDQ5Y1nZt62lAEy9b4Wghi6xAZjQ9l+TdfWBbPZrARnOYD2iwg82yFgvqGqfBP0J/yv7QdyNyfmpps1vU0SIa0YhGNKJN8FC0s1DXyt400qIFu4s4lTR7q6pr01kgeda0Ka5r1EISjWhEI9pPj1bZ90pvGkn/ZJJ9E4ImmdbgP12/pfX9rsEYkrGPVgkFLfiKdfP9rA3SQpu1tzTT7Sb4ZhtNLGDa20Ejo1mM0b5oZLB0C/0EdlfkawDsWeU2OjlsNrD5Aj/qJCeZxgqkWS+aHsvaapC16vcFaSk/uw3Cza60pAql66K+7H3djjsgsmcV24PinAOxrUVI+DVrsrOWheImL5CXFi4oYhm/8qXziA4I7q503mEYWW9gsnapCXH+bFb7BaJuomMma4jNCW5GejSzvsK2E3f12Fb1YaG2xL8eFp6oLGsJTlv2QPg7q4r8GYh6EeTFWQeif/UnvYVktA2N0craR528637Z0VgV81lda31hNNKclsCUzKdP8mc2+jl0ylrBTdc7bPwarlN2rbn/NbEwDb0RXDjgxZnn1NEiGtGIRrSQ06b3+rVQ5oNoRCMa0YhGNKIdpXeiTG9+iEY0ohGNgoKC4nRjdktUh35zZjtqhIcmr3zwl4r9YRbDRIPcy3onGXfnh6KZNSOTtsJCi6l8eYrhMmfW7i2psVJYaKISRXzU+XQomoDnHdEJDy3hQ7BYxRA0cPnP2+Gh8eUpMD8crRWmukZBQUFB8dP8AoFo4aOJuxH4Ycj3roMieiEasWmNe/qQ763eTJVDRAOXT1odcgSEmAxTifwOcXfYwouohokWxeGvXitjKUy02BEKWQuboWr8cfgWPRKyiUvl4QuZ8LNw0ezhx82yHi6acIT30rcHZ99eHH2qYyQkMxKO9jkiw3SdiUY0ohFtcFHP6aBVPXtJGZb2nR8q2npq+KxdL4SK9ropKjlUTLcrYL7tLR9Ck9Wi2DnXu773Bf5mb0Q6qbQ0S9mKqJj1Ys56FW0WD6EJW1lhC3rX9y5CZHfSs/bYF3VdVLJQbKEm/ME5hBZFrO88eXN9b3LNfTDhtPpVljWB03IWyJ8Yh9BsT3oOZnB9L3M2oTjpLWTtrtJKc5qASXjpHUL7C8RXMBVc31tw0zXshuqUXZna3sicTh0too2d9oEvg6MhpKkH04LVct/dImrG3HxHO2jl+0roaHsvN4zDaROYtRjqqSsNbN5Cv41Lac1Sq9i1O/kG1nq3iCovrLNX+7LWwrZRXXPTnUXRLUpZB1hPstJCPce/JJ+orJ0DiG1dF/VVvoDItgryom3d4AkLbhFV2FhSJb+vrklGlNEKVeN+1Gjf7vKeCSuQks9Xi5ksmgomO+qyzleFERz1IutjwGbEenOLKF+4q8T8vhayRytFrGzVi9xmpXNWMyryNzLrTU4UbRFUvsYLo0HirjLjq3+WA9rum1tEFWpL+2jPJT8T0KKGyWmsJ1nZMHrdyAmiNXQVyhqnlbULmPbUnMZpMXxziyhW1wZpcXyEnYDG6xqjsZ5kJYNqDp2JPa+JytSesqeYRn1IohGNaETbiyn+VfTME080ohGNaEQjGtHOrE9yiqFM74EnGtGIRjSiEY2CgoKC4mxixj/kZhEjjTm+osnq6f29KGL/ekSP+UM22BRkN+2NTBIfXH48ussealbvSQaNE+9h8IfPa/yhykV35g+5I8ZpxMAcxOCgzrJCc78JB0zjOw4t+v50loIOL9CaYYfszlUI7m0id87Z7u9wBMZKXIn5GjbSUF5YV1OfwyXc5jNN4v9+wIqMw1N30V1wCyej7U1nER1YBIgZIPOLemMLAIkS2NbHcWVEtPlYocqn2czDTVgGkIP9YFNGC0QVpFLLWjkZbW86C6OZSS/2NmsJn08jtqEijoqmCqXeNBtG+2O6yWlB1kQd4g5Ihn3And+GpvVNZ+GXekabvECyuhbfntkOsjYimqhvBLRgmg18zkshL5C8rn06pwZZOxlN7JvOco03i0EzAoLYYS0kr2sjokH5k4AWTLNhzUgGm7wZaSA2gxaS1bWT0Abjvcb/jKOv8adTNgUFBQUFxY+HMr17JhrRiHYWex7fsnO/BWXOGuUOxrfsXPVK0h3pnse37FwUj7DM2rHG3WNbdm4OcXG0exjfsnPu0CsaHjPGt+xcA/3R7mB8y86NfM/jW3ZOWhjxDsa37Jw48vbLGhcNDBp2HRyTcWfekeztdHqgJ73PoTKKvRGNaEQbB23f72Y/ftK0J5rW8fbTsnu0yuGwiaaJ7xbEmgiaUBrY92Bfcnha7D+O6M5v4PZOel3ZQD+baeEDTLKtDTYKjWNKjTsm/hN3c1qz8hn/4bVU+WwDn38N8F9Xszv506SxQf3DEhdJxh7ttXdcWu1/+agBT0Hoziwpz+S8aUFczwLbehocOZnT6vOx0kq8cMsDcVEo3fK+FfOvJD/PsmbdOFWavz9r2WMXyBYmqx4U+QG7q7iYysJjZDS2VdyjZUEVfq+DzvYVdwR2WItw8/XDfzm8QG6eOq0i4IJkpLHJNvIgYyqTtlJXjkFbBbvWyxqra8/4Qbo6py/ze3V9y4cVq5CSAlppRShU+FAjwWjsv6IFc9v2TpsWFEh7NysZ84JTyVmv2AcS1Vjp3DGyJqsQXerVNXzE6hpLWEbTc6yu6bk0o7XYMevReF3j43qN0VhdS5SqzQ1tJFlrA6Opol5p8S+1snFHdNQzOWUn/NGdsns023rKaLM8axBkLVE6E1p5/9zB0y6QMfxYMvD/7J3Bc9pWHsefBBI27oFnEQyODyKB3Xh6kWySjHsCkyXupAesJpNNc0E2yYxzgrqJmxt22LS9mTTr9U4uZKdtZnuyZ7e7sz3Zk/5h+/v9hGOwIRZGUESkGQcyfpbeR7/3pO97T/r+wpqBjobQQ6CvDSZqgxBab0ZVQ0rv/CQ9eWxjp/PwY/LJUURb+L7xPO7woRm9NsjvdiFqdcZu89vhAj0uy6TalFybEo0IMzV9hWf9PCtUSwNGM3pHY5sq8y0ydmdM8av4uKzGpLr+Sak4l8WbzgbJg1tCnbkPDaJGsTd8Ibhp4oOXoMGFKt5t8PHBCMgDcqtzHG2B/wRaFYcUSpDv6DqZYYPmScYLLBX+lkfv4UikhP89f1/72Jc9gXb4qKHH79VBHqBbnfNoswxl+L3CP5kyW3ihq2SGDeMLGIcwGHIY7I4vYg1Lzom2Cj8pfNS9GY1PyjW+gmiHmogDuZt9QHsUe45RgyGFUuZTOiMzbBhfJGnVAYYchhyhYYmT97Uml85kH6+QYhpGGDSkmC3AUInMsOE/eEgYctxHtDdWDfqBJn/WP7Q4r8AIw4B+BX0tqjMyw8a+hu0oXNmMAhoNS1ysRnyRk/exURFaeuPNoPe8ReNpyA8aLTgD97MBoukDRfNNDgOa0g+0idxoRS3D64d/jxXK4RnmL7F9ru7/sNdHNEsiJjLohS1U1zNL4g2cg9nnczdiD3lsVYkq8BuRX3Aian7lML98aRqiBvrqojSzz/uJ1pCIDxfRC7vuV6srueK3PD3DxFxRZebbSabAb/SDpANo+3zmsL7/8SSg/QCtcuLivtrPBnkkEe+SF7ZZEFby/gpjiamVvLS+zJ+FAI1tVJkDaOKFIKJdgnDJk4yi1m80lIjyEqH51YSFxvxb+eI322YDTdd+7B1Nrn2KaOrypzMiXEX2w2rf0UAixnmd0HzQ1xBNzsRW+LQvk2mgBfifHL1l++sDu2W3GVocLdw0tjeOoukHQ4NGE5Se0HIX2gTe1kYTTedX3YhmsNMZRcT8cU+T+VQvaD6unS4Sf1dG0PoctdNoLTHTxPOjjbe5dcnKO7BTaAGedS5qQi26yZ9lolLyhlp8C5+1KZN/iWuxoC8XeB1n7IVzo/nbhOXdsyRt0Bj72UE0NSGp/spv0o6YTuBnXl+BBrk4lgN9OQshXGLnQEPBrW/xbDlME7SPKBeNiOkuKszP1610M2Vu1qI+PKtLfAp0eVEtHuBCtmNoWlVSTc4fqHJ2lz5NQKPnHuTIo1gFddc50EBwqyntV0GjCVqcvgWVrWGiQjKzoHQzEDWVziZ83wRdfiVdZVd3nEXbg/pDh/sqR5/myrb13IMcIceR86CR4N7kYUEj9U3Tt6CyKbWML9RIN4MNskpncwwnk6Un2V1WZY6ijUFfCwOaqfrw01zNUF8DtDg/Z9RIcKc0qD1N0NL07QZGjVkWJJRuRjiAg9PZ9O8druSLldm0C9QICW4RV2BogpambzdEK7WML9RIN4Npaap0NkWeAT0O59bJqPUJrXvbDbzjpAouiNr50F558thD89A8NA/NnWgj/CbUwAI7lEf20Dw0D81D89A8NLeiDTSDzGAT2YQGeT5DA92Dh+aheWhuvHh7m7d52we2/Y/pmq2C8bpfHdjBHKlGUX1lr2BiqXc02wdzpBq+W7k1XqqenYEjkSiq8VhvJ932wZypRhlXsm2YsSeKX11WAvnezrndgzlTDR19DxYunHkeEiK/kvale0OzezBnqqHT29Cn35U/tU+WuawE872i2TuYM9XQ2RqPLIfPjhrb7Lmv2T5Yn6vhbd7mbd7mbd7ciIc2VGh2vdgdcYvv3fi9m2rY9WJ3xC2+d+P3bqph14vdEbf43o3fu6mGXS92R9ziezd+76oadr3YHXGL7934vZtq2PVid8Qtvnfj926qYdeL3RHP9t530s0e7HqxO+IW37vxezfVsOvF7ohbfO/G711VQ7VZzpFhu9rzHj7M2QOba/x2n1EUeB83GzUJdSUvQzZVqPDun76Ot0K21bKH5qF5aEdblwl6hxqt8b5u404t38y6DK1MS2aS2vwecuP12Va0NTVVcBXaRBbdJU+9YN0G7RcW2HYVmv+AzdIL1n/BVZQYr+DCpzAfC2spfim/iKYi6P8ohtwXNVNjVXrBWsIVy0kxjQufwrwilRYhaoD2I/k/Aprr+hpFTdMfqBKuWCpjaVz4FOZDgScRC83yf6TO5rIrZAD6mqD9W9qTcMUS0HDhE9EoanfFiOX/KIZYt9tQXCEFnh2z+hqg4cInoWFf02PoNh/kUVeisfcYXLhfjYwwmqchPTQP7fdCa76w+DruTV5693U53/zX1z4bJrTlxjNzlu15B7QTnm2BvaNvH+VaTwyqzWFAG8dUB3cbE6jG+6J2Au04kUDrLwRtvDJMaGwpE9aiGR410P9fO8oKcCO2CqOA6M0Ur6R4nD+pXRQzsdqMqekF9h2DMYOUzKET0xYmDXiM3+Ua1ybqw4Q2FmH+vWmrQd5CtLz+qFScyxUvwyhgGl2DUFQG66m5nKk+DpQ2GPsjwzHDThCK5dFoqE7fP8kL2lh+iNCW+fMyLymIZvn/S6pZxKwA0jroSQVdg3Ao4K9IW1D1pC8XITQcM/ixGBkNSfi9WhkeNNrusrHIOKDdZ4bl/w9olBWg+AzR0DUIorYdrOtziMbuQZODBgljBjWIxchoiL5DkaFpkA00uRYGhM2oYfn/A9rDGkeLTkJL8XSKX85gXyO0Qw0vIzBmkFRKHkBGQ/R9NVMbmsuIjUmt01uSLv6dhPWwXPzPg0aZAuSlDmjyUN2yPQ3poTmNpudHAq1ptrd45HD/NPKeHRonenw3aO9fntdPVqgtWrsKn0SLkzFnoyR6n/5ydFnKvmja4QLfbbnQnYW2rJpaJyblmCJ54vpvA61jhU+hJdgXzSUZ+8dR9dPVph2+AhlkM2oktG5HTO3MqOnniVrHCrdBe4FOnVc4L6qmyb/8M49wUud+tdikAf6Kc95V0bhQl/4DAh6ids0qFufzmWgbeXzH1JYvQIFry2G/aq4YkTjPK0GehvGAQplnEpmdTDjpI+P+1do0RI0GB9N6AJTla67Gw1rLK26hsyrcpkEuolOnyu76ySAUs8yab0Gd64VAkyi9zj9HtKwvQgKeGiQWW1cY/HkbND0+l1sDlb8OIwDYcRaTyCoJUBX+PYWyPKGTKEtaxv1b29ggcXCQZ4i2lZMuZyfqbdE6VrhN1PQ4OnWulY5K+tA9P1Aqo6VnU+d9imh5ZvyXlLkhzFOxr9PM5LxwGi3Ir5dEVPn7i7RjTCKrbDCZxgOY5YmcRJOWcf/z17uIBoODCqF9U8KopDs0yA4VboeWqjDpDy+YVIqj96kRQPd8LNm8w132WKjcBrRqlpS5IVynYhS1dvJY5jg2w/3oD2DHecoNmihY4wHM8oROooXkkXF/wkLDqInp1Bb8aZaxDg2yY4VPNchJdOq8xPk8r6H3qUHu+SfR9vmOyF8Cmj9PyhyiZhXDvhZup/zL2NeAnU/5eG0lj0lkFYnnaDyAfS3O62tWX4MGyKMW2kPoa3Lm5fPaDTXOSx0aZMcK/25q5MS7askB3bIHgHYyiewIoXny2EPz0AaDZowUWpz/dAw2UmgTWfnzEURLTdIzJMy4vSh/1pLN1aRkAZTs1Z1or1Eywz36XqE6lm7N5irP6NrPlOzVvWiomw1WXHjeks31KtrOJyjZq3sbJPY1g4kvW7O5PpUB7W+U7NXFV8gyf2IwebI1m2sqHNX5DiV7dft9zZdrO/1hMPejje+1Q/soMgJonob00Dy0QaFZ64Vts4Q1jwuSLkKT+HQDDa/04yo7G631/YAhRisVD46j5tdsoblDaEklXcvgqkDeEPn35TClCAvySUpSFLVm+B+z+6haMMVaMsCb3g8Ybnks8UUI1r8UaJC69ljQKEVYomCYmFrqN2uG33yI9+7A9hc+BaL29Pj9gCFHe/JKLvOv04BWZSl8OqTMpzYYov1/kOvVUhoYWLULGBhUBB2CGCRUmUD3TcH2Bwz2BJnSIcZZLMwFirWlIK9pJoCuemNsCIFcrwaMNWYXUAeO2yGIR0w18QDy/oBBXowwS0wUKSiUBOc1kNe4BCUyBZ2YBKdArldLmygFmrhjCBRxCBRUUGUVdEHsDxiSVTZKm5+N6I01Q85r3BNGG1qjXhv12qjXRr1GZ68N45MrRsEoGAWjYBSMglEwCgYKAAAWblFnZCRJMQAAAABJRU5ErkJggg=="/></div><div class="graphic_lgnd">The management of patients with VHL disease and RCC is evolving. Patients with VHL disease and renal masses should seek multidisciplinary care from clinicians familiar with VHL management guidelines, including a nephrologist, urologist, medical oncologist, interventional radiologist, and clinical geneticist. Clinical trials are encouraged, where available.</div><div class="graphic_footnotes">VHL: von Hippel-Lindau; RCC: renal cell carcinoma; mm: millimeters.<br/>* Kidney transplantation has been safely used in patients with VHL disease and RCC, although experience is limited. Refer to UpToDate topics on kidney transplantation in adults.<br/>¶ Patients ineligible for surgery or other nephron-sparing approaches include those with multiple prior surgeries or those with lesions in a solitary remaining kidney where further locoregional interventions would render the patient anephric.<br/>Δ Belzutifan is an alternative to surveillance for patients with rapidly growing tumors or those who desire a more aggressive management strategy, in order to potentially postpone or avoid future surgical interventions.<br/><span class="lozenge">◊</span> Surgery is preferred in most patients with resectable RCC. Nonsurgical options such as radiofrequency ablation and cryotherapy represent less invasive alternatives for select populations, such as older adults, those with significant comorbidities, or those with the need to preserve kidney parenchyma (eg, solitary kidney, multiple lesions). Refer to UpToDate content on radiofrequency ablation and cryoablation for RCC.</div><div id="graphicVersion">Graphic 134083 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
